{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:28:54Z","timestamp":1793183334061,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":102,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EMBARC4"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Prim. Care Respir. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bronchiectasis is a common chronic respiratory disease with rising prevalence, hospitalisation rates, and mortality. It is estimated to affect approximately 1 in 200 adults, imposing a substantial symptom burden and significant healthcare costs, largely driven by exacerbations. Although diagnosis and long-term management are usually led by respiratory specialists, most patient care interactions occur in primary care, including the management of multimorbidity and acute exacerbations. In December 2025, the European Respiratory Society (ERS) published updated global clinical practice guidelines for adult bronchiectasis. This article summarises the 2025 ERS recommendations with a specific focus on their implementation in primary care practice. Key priorities include improving early recognition and reducing diagnostic delay, undertaking standardised investigations to identify underlying causes and treatable traits, and recognising features associated with poor outcomes that warrant specialist referral. The guidance emphasises the importance of sputum microbiology, including testing for non-tuberculous mycobacteria, and targeted blood investigations such as immunoglobulins and allergic bronchopulmonary aspergillosis serology. Core management strategies relevant to primary care are reviewed, including airway clearance techniques, pulmonary rehabilitation, and evidence-based use of inhaled therapies. The article outlines best practice for the management of acute exacerbations, highlights differences from asthma and COPD care, and clarifies the limited role of inhaled corticosteroids in bronchiectasis. The identification and monitoring of patients who may benefit from long-term antibiotic therapy, including those with\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    infection, are also discussed. By translating specialist guideline recommendations into a primary care context, this summary aims to support timely diagnosis, optimise ongoing management, and improve outcomes for adults with bronchiectasis.\n                  <\/jats:p>","DOI":"10.1038\/s41533-026-00528-z","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:06:17Z","timestamp":1780945577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The European respiratory society guideline for adult bronchiectasis 2025: summary and implementation guide for primary care"],"prefix":"10.1038","volume":"36","author":[{"given":"Fiona","family":"Mosgrove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janwillem WH","family":"Kocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Kompatsiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Timothy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Hedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete B.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"528_CR1","doi-asserted-by":"publisher","first-page":"2500909","DOI":"10.1183\/13993003.00909-2025","volume":"66","author":"E Bacopanos","year":"2025","unstructured":"Bacopanos, E. et al. The increasing burden of bronchiectasis in the UK. Eur. Respir. J. 66, 2500909 (2025).","journal-title":"Eur. Respir. J."},{"key":"528_CR2","doi-asserted-by":"publisher","first-page":"2301554","DOI":"10.1183\/13993003.01554-2023","volume":"63","author":"S Aliberti","year":"2024","unstructured":"Aliberti, S. et al. Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC). Eur. Respir. J. 63, 2301554 (2024).","journal-title":"Eur. Respir. J."},{"key":"528_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1183\/13993003.01033-2015","volume":"47","author":"JK Quint","year":"2016","unstructured":"Quint, J. K. et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur. Respir. J. 47, 186\u2013193 (2016).","journal-title":"Eur. Respir. J."},{"key":"528_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19956-y","volume":"24","author":"L Wang","year":"2024","unstructured":"Wang, L., Wang, J., Zhao, G. & Li, J. Prevalence of bronchiectasis in adults: a meta-analysis. BMC Public. Health 24, 2675 (2024).","journal-title":"BMC Public. Health"},{"key":"528_CR5","doi-asserted-by":"publisher","first-page":"240049","DOI":"10.1183\/16000617.0049-2024","volume":"33","author":"JD Chalmers","year":"2024","unstructured":"Chalmers, J. D. et al. A systematic literature review of the clinical and socioeconomic burden of bronchiectasis. Eur. Respir. Rev. 33, 240049 (2024).","journal-title":"Eur. Respir. Rev."},{"key":"528_CR6","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S2213-2600(25)00160-2","volume":"13","author":"O Sibila","year":"2025","unstructured":"Sibila, O. et al. Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study. Lancet Respir. Med. 13, 911\u2013920 (2025).","journal-title":"Lancet Respir. Med."},{"key":"528_CR7","doi-asserted-by":"publisher","first-page":"2501126","DOI":"10.1183\/13993003.01126-2025","volume":"66","author":"JD Chalmers","year":"2025","unstructured":"Chalmers, J. D. et al. European Respiratory Society clinical practice guideline for the management of adult bronchiectasis. Eur. Respir. J. 66, 2501126 (2025).","journal-title":"Eur. Respir. J."},{"key":"528_CR8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S2213-2600(16)30320-4","volume":"4","author":"MJ McDonnell","year":"2016","unstructured":"McDonnell, M. J. et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir. Med. 4, 969\u2013979 (2016).","journal-title":"Lancet Respir. Med."},{"key":"528_CR9","doi-asserted-by":"publisher","first-page":"2301504","DOI":"10.1183\/13993003.01504-2023","volume":"64","author":"A Spinou","year":"2024","unstructured":"Spinou, A. et al. Diagnostic delay and access to care in bronchiectasis: data from the EMBARC\/ELF patient survey. Eur. Respir. J. 64, 2301504 (2024).","journal-title":"Eur. Respir. J."},{"key":"528_CR10","doi-asserted-by":"publisher","first-page":"00713","DOI":"10.1183\/23120541.00713-2023","volume":"10","author":"C Chessari","year":"2024","unstructured":"Chessari, C. et al. Diagnostic delay in bronchiectasis: an Italian perspective. ERJ Open. Res. 10, 00713\u201302023 (2024).","journal-title":"ERJ Open. Res."},{"key":"528_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1164\/rccm.202309-1614OC","volume":"210","author":"E Polverino","year":"2024","unstructured":"Polverino, E. et al. The association between bronchiectasis and chronic obstructive pulmonary disease: data from the European Bronchiectasis Registry (EMBARC). Am. J. Respir. Crit. Care Med. 210, 119\u2013127 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"528_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","volume":"10","author":"S Aliberti","year":"2022","unstructured":"Aliberti, S. et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respir. Med. 10, 298\u2013306 (2022).","journal-title":"Lancet Respir. Med."},{"key":"528_CR13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.semarthrit.2021.08.005","volume":"51","author":"LW Martin","year":"2021","unstructured":"Martin, L. W. et al. Prevalence and risk factors of bronchiectasis in rheumatoid arthritis: a systematic review and meta-analysis. Semin. Arthritis Rheum. 51, 1067\u20131080 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"528_CR14","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.3390\/jcm12185782","volume":"12","author":"JD G\u00f3mez-Olivas","year":"2023","unstructured":"G\u00f3mez-Olivas, J. D., Oscullo, G. & Mart\u00ednez-Garc\u00eda, M. Etiology of bronchiectasis in the world: data from the published national and international registries. J. Clin. Med. 12, 5782 (2023).","journal-title":"J. Clin. Med."},{"key":"528_CR15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","volume":"189","author":"JD Chalmers","year":"2014","unstructured":"Chalmers, J. D. et al. The bronchiectasis severity index. an international derivation and validation study. Am. J. Respir. Crit. Care Med. 189, 576\u2013585 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"528_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","volume":"11","author":"JD Chalmers","year":"2023","unstructured":"Chalmers, J. D. et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir. Med. 11, 637\u2013649 (2023).","journal-title":"Lancet Respir. Med."},{"key":"528_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.rmed.2018.10.031","volume":"145","author":"D Radovanovic","year":"2018","unstructured":"Radovanovic, D. et al. A comprehensive approach to lung function in bronchiectasis. Respir. Med. 145, 120\u2013129 (2018).","journal-title":"Respir. Med."},{"key":"528_CR18","doi-asserted-by":"publisher","first-page":"2400061","DOI":"10.1183\/13993003.00061-2024","volume":"63","author":"R Agarwal","year":"2024","unstructured":"Agarwal, R. et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis\/mycoses. Eur. Respir. J. 63, 2400061 (2024).","journal-title":"Eur. Respir. J."},{"key":"528_CR19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.chest.2024.06.3843","volume":"167","author":"J Pollock","year":"2025","unstructured":"Pollock, J. et al. Aspergillus serologic findings and clinical outcomes in patients with bronchiectasis: data from the European bronchiectasis registry. Chest 167, 975\u2013992 (2025).","journal-title":"Chest"},{"key":"528_CR20","doi-asserted-by":"publisher","first-page":"2400907","DOI":"10.1183\/13993003.00907-2024","volume":"64","author":"PY Tiew","year":"2024","unstructured":"Tiew, P. Y. et al. Residential exposure to aspergillus spp. is associated with exacerbations in COPD. Eur. Respir. J. 64, 2400907 (2024).","journal-title":"Eur. Respir. J."},{"key":"528_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley, C. L. et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin. Infect. Dis. 71, 905\u2013913 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"528_CR22","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3390\/ijms17111913","volume":"17","author":"P Faverio","year":"2016","unstructured":"Faverio, P. et al. Characterizing non-tuberculous mycobacteria infection in bronchiectasis. Int. J. Mol. Sci. 17, 1913 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"528_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","volume":"74","author":"A T Hill","year":"2019","unstructured":"T Hill, A. et al. British thoracic society guideline for bronchiectasis in adults. Thorax 74, 1\u201369 (2019).","journal-title":"Thorax"},{"key":"528_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.rmed.2016.08.008","volume":"119","author":"G Bellelli","year":"2016","unstructured":"Bellelli, G. et al. Characterization of bronchiectasis in the elderly. Respir. Med. 119, 13\u201319 (2016).","journal-title":"Respir. Med."},{"key":"528_CR25","doi-asserted-by":"publisher","first-page":"2202053","DOI":"10.1183\/13993003.02053-2022","volume":"62","author":"B Herrero-Cortina","year":"2023","unstructured":"Herrero-Cortina, B. et al. European respiratory society statement on airway clearance techniques in adults with bronchiectasis. Eur. Respir. J. 62, 2202053 (2023).","journal-title":"Eur. Respir. J."},{"key":"528_CR26","doi-asserted-by":"publisher","first-page":"2301689","DOI":"10.1183\/13993003.01689-2023","volume":"63","author":"A Spinou","year":"2024","unstructured":"Spinou, A. et al. Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC). Eur. Respir. J. 63, 2301689 (2024).","journal-title":"Eur. Respir. J."},{"key":"528_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1471-2466-14-107","volume":"14","author":"AR McCullough","year":"2014","unstructured":"McCullough, A. R. et al. Treatment adherence and health outcomes in patients with bronchiectasis. BMC Pulm. Med. 14, 107 (2014).","journal-title":"BMC Pulm. Med."},{"key":"528_CR28","unstructured":"European Lung Foundation ERS. Managing my bronchiectasis, patient priorities. 2026 https:\/\/europeanlunginfo.org\/bronchiectasis\/self-management\/."},{"key":"528_CR29","unstructured":"Bronchiectasis toolbox: Airway clearance videos. https:\/\/bronchiectasis.com.au\/resources\/airway-clearance-videos."},{"key":"528_CR30","doi-asserted-by":"crossref","unstructured":"E R. Nurse-led oscillating positive expiratory pressure. Independent Nurse2024.","DOI":"10.12968\/indn.2024.5.12"},{"key":"528_CR31","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJMoa2510095","volume":"393","author":"JM Bradley","year":"2025","unstructured":"Bradley, J. M. et al. Hypertonic saline or carbocisteine in bronchiectasis. N. Engl. J. Med. 393, 1565\u20131577 (2025).","journal-title":"N. Engl. J. Med."},{"key":"528_CR32","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.2147\/COPD.S474512","volume":"19","author":"P Rogliani","year":"2024","unstructured":"Rogliani, P., Manzetti, G. M., Gholamalishahi, S., Cazzola, M. & Calzetta, L. Impact of N-acetylcysteine on mucus hypersecretion in the airways: a systematic review. Int. J. Chron. Obstruct Pulmon Dis. 19, 2347\u20132360 (2024).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"528_CR33","first-page":"Cd013110","volume":"4","author":"AL Lee","year":"2021","unstructured":"Lee, A. L., Gordon, C. S. & Osadnik, C. R. Exercise training for bronchiectasis. Cochrane Database Syst. Rev. 4, Cd013110 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"key":"528_CR34","doi-asserted-by":"publisher","first-page":"1801264","DOI":"10.1183\/13993003.01264-2018","volume":"53","author":"S Patel","year":"2019","unstructured":"Patel, S. et al. Pulmonary rehabilitation in bronchiectasis: a propensity-matched study. Eur. Respir. J. 53, 1801264 (2019).","journal-title":"Eur. Respir. J."},{"key":"528_CR35","doi-asserted-by":"publisher","first-page":"2400518","DOI":"10.1183\/13993003.00518-2024","volume":"63","author":"H Choi","year":"2024","unstructured":"Choi, H., McShane, P. J., Aliberti, S. & Chalmers, J. D. Bronchiectasis management in adults: state of the art and future directions. Eur. Respir. J. 63, 2400518 (2024).","journal-title":"Eur. Respir. J."},{"key":"528_CR36","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","volume":"7","author":"JD Chalmers","year":"2019","unstructured":"Chalmers, J. D. et al. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir. Med. 7, 845\u2013854 (2019).","journal-title":"Lancet Respir. Med."},{"key":"528_CR37","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/thoraxjnl-2019-213929","volume":"75","author":"D Smith","year":"2020","unstructured":"Smith, D. et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax 75, 370\u2013404 (2020).","journal-title":"Thorax"},{"key":"528_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cgh.2014.07.054","volume":"13","author":"MA Martinez","year":"2015","unstructured":"Martinez, M. A. et al. Clinical and histologic features of azithromycin-induced liver injury. Clin. Gastroenterol. Hepatol. 13, 369\u201376.e3 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"528_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.chest.2024.01.045","volume":"166","author":"R Cordeiro","year":"2024","unstructured":"Cordeiro, R., Choi, H., Haworth, C. S. & Chalmers, J. D. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: updated systematic review and meta-analysis. Chest 166, 61\u201380 (2024).","journal-title":"Chest"},{"key":"528_CR40","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","volume":"392","author":"JD Chalmers","year":"2025","unstructured":"Chalmers, J. D. et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N. Engl. J. Med. 392, 1569\u20131581 (2025).","journal-title":"N. Engl. J. Med."},{"key":"528_CR41","doi-asserted-by":"publisher","first-page":"2401551","DOI":"10.1183\/13993003.01551-2024","volume":"65","author":"JD Chalmers","year":"2025","unstructured":"Chalmers, J. D. et al. Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study. Eur. Respir. J. 65, 2401551 (2025).","journal-title":"Eur. Respir. J."},{"key":"528_CR42","doi-asserted-by":"publisher","first-page":"230178","DOI":"10.1183\/16000617.0178-2023","volume":"33","author":"M Concei\u00e7\u00e3o","year":"2024","unstructured":"Concei\u00e7\u00e3o, M., Shteinberg, M., Goeminne, P., Altenburg, J. & Chalmers, J. D. Eradication treatment for pseudomonas aeruginosa infection in adults with bronchiectasis: a systematic review and meta-analysis. Eur. Respir. Rev. 33, 230178 (2024).","journal-title":"Eur. Respir. Rev."},{"key":"528_CR43","doi-asserted-by":"publisher","first-page":"2500054","DOI":"10.1183\/13993003.00054-2025","volume":"66","author":"KX Thng","year":"2025","unstructured":"Thng, K. X. et al. Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study. Eur. Respir. J. 66, 2500054 (2025).","journal-title":"Eur. Respir. J."},{"key":"528_CR44","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1513\/AnnalsATS.201506-333OC","volume":"12","author":"S Finch","year":"2015","unstructured":"Finch, S., McDonnell, M. J., Abo-Leyah, H., Aliberti, S. & Chalmers, J. D. A Comprehensive analysis of the impact of pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 12, 1602\u20131611 (2015).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"528_CR45","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1164\/rccm.202501-0159OC","volume":"211","author":"RC Hull","year":"2025","unstructured":"Hull, R. C. et al. Endotypes of pseudomonas aeruginosa infection in bronchiectasis are associated with inhaled antibiotic response: results from two randomized, double-blind, placebo-controlled phase III trials (ORBIT 3 and ORBIT 4). Am. J. Respir. Crit. Care Med. 211, 1397\u20131408 (2025).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"528_CR46","doi-asserted-by":"publisher","first-page":"00938","DOI":"10.1183\/23120541.00938-2023","volume":"10","author":"YH Gao","year":"2024","unstructured":"Gao, Y. H. et al. A phase 4 multicentre, 2\u2009\u00d7\u20092 factorial randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of tobramycin inhalation solution for pseudomonas aeruginosa eradication in bronchiectasis: ERASE. ERJ Open. Res. 10, 00938\u201302023 (2024).","journal-title":"ERJ Open. Res."},{"key":"528_CR47","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1183\/13993003.01778-2020","volume":"56","author":"JD Chalmers","year":"2020","unstructured":"Chalmers, J. D. & Miravitlles, M. Withdrawal of inhaled corticosteroids in COPD. Eur. Respir. J. 56, 1267\u20131280 (2020).","journal-title":"Eur. Respir. J."},{"key":"528_CR48","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/thorax-2024-221825","volume":"80","author":"J Pollock","year":"2025","unstructured":"Pollock, J. et al. Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC). Thorax 80, 358\u2013368 (2025).","journal-title":"Thorax"},{"key":"528_CR49","unstructured":"BTS\/SIGN\/NICE\u00a3. Asthma pathway. 2025."},{"key":"528_CR50","doi-asserted-by":"publisher","unstructured":"Venkatesan P. 2025 GINA report for asthma. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(25)00242-5 (2025).","DOI":"10.1016\/S2213-2600(25)00242-5"},{"key":"528_CR51","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino, E. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 50, 1700629 (2017).","journal-title":"Eur. Respir. J."},{"key":"528_CR52","doi-asserted-by":"publisher","first-page":"1700051","DOI":"10.1183\/13993003.00051-2017","volume":"49","author":"AT Hill","year":"2017","unstructured":"Hill, A. T. et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur. Respir. J. 49, 1700051 (2017).","journal-title":"Eur. Respir. J."},{"key":"528_CR53","doi-asserted-by":"publisher","first-page":"2500081","DOI":"10.1183\/13993003.00081-2025","volume":"66","author":"JD Chalmers","year":"2025","unstructured":"Chalmers, J. D. et al. Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target. Eur. Respir. J. 66, 2500081 (2025).","journal-title":"Eur. Respir. J."},{"key":"528_CR54","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/resp.12228","volume":"19","author":"JD Chalmers","year":"2014","unstructured":"Chalmers, J. D. & Finch, S. Sputum colour in non-CF bronchiectasis: the original neutrophil biomarker. Respirology 19, 153\u2013154 (2014).","journal-title":"Respirology"}],"container-title":["npj Primary Care Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41533-026-00528-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-026-00528-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-026-00528-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:02:59Z","timestamp":1789689779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41533-026-00528-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["528"],"URL":"https:\/\/doi.org\/10.1038\/s41533-026-00528-z","relation":{},"ISSN":["2055-1010"],"issn-type":[{"value":"2055-1010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D. Chalmers reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Grifols, Novartis, Insmed, and other industry partners; and consulting or personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Insmed, Novartis, Janssen, Zambon, Antabio, and others, outside the submitted work.S. Aliberti reports receiving research grants and institutional funding from AstraZeneca, Chiesi, GlaxoSmithKline, Insmed, Zambon, Novartis, Boehringer Ingelheim, Menarini, and Pfizer; and personal fees or advisory board honoraria from AstraZeneca, Chiesi, GSK, Insmed, Zambon, Novartis, Boehringer Ingelheim, Menarini, and Pfizer, outside the submitted work.. Kochs reports receiving research funding from Insmed, Zambon, Chiesi, Novartis, AstraZeneca, GlaxoSmithKline, Menarini, and Boehringer Ingelheim; and personal fees or advisory board honoraria from Insmed, Zambon, Chiesi, Novartis, AstraZeneca, GSK, Menarini, and Boehringer Ingelheim, outside the submitted work.FM has received personal fees or advisory board honoraria from AstraZeneca, Chiesi, GSK, Insmed, Trudell and Viatris.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"62"}}